Fitzgerald Collette, Patrick Mary, Gonzalez Anthony, Akin Joshua, Polage Christopher R, Wymore Kate, Gillim-Ross Laura, Xavier Karen, Sadlowski Jennifer, Monahan Jan, Hurd Sharon, Dahlberg Suzanne, Jerris Robert, Watson Renee, Santovenia Monica, Mitchell David, Harrison Cassandra, Tobin-D'Angelo Melissa, DeMartino Mary, Pentella Michael, Razeq Jafar, Leonard Celere, Jung Carrianne, Achong-Bowe Ria, Evans Yaaqobah, Jain Damini, Juni Billie, Leano Fe, Robinson Trisha, Smith Kirk, Gittelman Rachel M, Garrigan Charles, Nachamkin Irving
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J Clin Microbiol. 2016 May;54(5):1209-15. doi: 10.1128/JCM.01925-15. Epub 2016 Mar 9.
The use of culture-independent diagnostic tests (CIDTs), such as stool antigen tests, as standalone tests for the detection of Campylobacter in stool is increasing. We conducted a prospective, multicenter study to evaluate the performance of stool antigen CIDTs compared to culture and PCR for Campylobacter detection. Between July and October 2010, we tested 2,767 stool specimens from patients with gastrointestinal illness with the following methods: four types of Campylobacter selective media, four commercial stool antigen assays, and a commercial PCR assay. Illnesses from which specimens were positive by one or more culture media or at least one CIDT and PCR were designated "cases." A total of 95 specimens (3.4%) met the case definition. The stool antigen CIDTs ranged from 79.6% to 87.6% in sensitivity, 95.9 to 99.5% in specificity, and 41.3 to 84.3% in positive predictive value. Culture alone detected 80/89 (89.9% sensitivity) Campylobacter jejuni/Campylobacter coli-positive cases. Of the 209 noncases that were positive by at least one CIDT, only one (0.48%) was positive by all four stool antigen tests, and 73% were positive by just one stool antigen test. The questionable relevance of unconfirmed positive stool antigen CIDT results was supported by the finding that noncases were less likely than cases to have gastrointestinal symptoms. Thus, while the tests were convenient to use, the sensitivity, specificity, and positive predictive value of Campylobacter stool antigen tests were highly variable. Given the relatively low incidence of Campylobacter disease and the generally poor diagnostic test characteristics, this study calls into question the use of commercially available stool antigen CIDTs as standalone tests for direct detection of Campylobacter in stool.
使用非培养诊断检测方法(CIDTs),如粪便抗原检测,作为粪便中弯曲杆菌检测的独立检测方法的情况正在增加。我们进行了一项前瞻性多中心研究,以评估粪便抗原CIDTs与培养法和PCR法相比在弯曲杆菌检测中的性能。在2010年7月至10月期间,我们用以下方法检测了2767份来自胃肠道疾病患者的粪便标本:四种弯曲杆菌选择性培养基、四种商用粪便抗原检测方法和一种商用PCR检测方法。通过一种或多种培养基或至少一种CIDT和PCR检测呈阳性的标本所对应的疾病被指定为“病例”。共有95份标本(3.4%)符合病例定义。粪便抗原CIDTs的敏感性在79.6%至87.6%之间,特异性在95.9%至99.5%之间,阳性预测值在41.3%至84.3%之间。仅培养法检测出80/89例(敏感性89.9%)空肠弯曲杆菌/结肠弯曲杆菌阳性病例。在至少一种CIDT检测呈阳性的209份非病例标本中,只有一份(0.48%)在所有四种粪便抗原检测中均呈阳性,73%仅在一种粪便抗原检测中呈阳性。非病例比病例出现胃肠道症状的可能性更小,这一发现支持了未经证实的粪便抗原CIDT阳性结果的相关性存疑。因此,虽然这些检测方法使用方便,但弯曲杆菌粪便抗原检测的敏感性、特异性和阳性预测值差异很大。鉴于弯曲杆菌病的发病率相对较低且诊断检测特征普遍较差,本研究对使用市售粪便抗原CIDTs作为粪便中弯曲杆菌直接检测的独立检测方法提出了质疑。